AbbVie had a positive start to 2022 with total net revenue and adjusted earnings exceeding the expectations of the management. The company is seeing positive momentum over various important portfolios and products, which include strong operational revenue growth from Aesthetics, Neuroscience, Rinvoq, and Skyrizi. Skyrizi has been performing particularly well for AbbVie. In psoriasis, the company has been achieving good profits and the recent launch of Skyrizi in psoriatic arthritis and the antic ....
28 May 2022
AbbVie Inc.: Acquisition-Led Growth Strategy & Other Drivers, Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (05/22)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
AbbVie Inc.: Acquisition-Led Growth Strategy & Other Drivers, Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (05/22)
- Published:
28 May 2022 -
Author:
Ishan Majumdar -
Pages:
27
AbbVie had a positive start to 2022 with total net revenue and adjusted earnings exceeding the expectations of the management. The company is seeing positive momentum over various important portfolios and products, which include strong operational revenue growth from Aesthetics, Neuroscience, Rinvoq, and Skyrizi. Skyrizi has been performing particularly well for AbbVie. In psoriasis, the company has been achieving good profits and the recent launch of Skyrizi in psoriatic arthritis and the antic ....